抗结直肠癌致病具核梭杆菌的潜在治疗靶点及其小分子配体

Progress of potential therapeutic targets and small molecule ligands of anti-colorectal cancer pathogenic Fusobacterium nucleatum

肠道微生物区系组成与结直肠癌(colorectal cancer,CRC)的发生发展联系密切,已有证据表明具核梭杆菌(Fusobacterium nucleatum)与结直肠癌的复发、转移、化疗耐药等密切相关。因此,探索潜在抗具核梭杆菌药物靶点并发现小分子药物,对于结直肠癌的预防、治疗具有重要意义,已逐渐成为该领域研究热点。但目前尚无特异性抗具核梭杆菌小分子药物,仍不清楚其是否能够“抗菌进而抗癌”以及具体作用机制。鉴于此,本文对具核梭杆菌感染促结直肠癌发生发展的潜在治疗靶点及其小分子配体进行综述,以期为开发抗具核梭杆菌进而抗结直肠癌的小分子药物提供参考。

The composition of intestinal microflora is closely related to the occurrence and development of colorectal cancer(CRC).Among them,Fusobacterium nucleatum(Fn)has been proved directly related to the recurrence,metastasis and chemotherapy resistance of CRC.Therefore,it is of great significance for the prevention and treatment of colorectal cancer by the exploration potential anti-Fn drug targets and discovery small molecule drugs.However,no selective anti-Fn small molecule inhibitors have been reported so far as well as their anti-Fn thereby"anti-Fn further anticancer"mechanisms are unclear.Herein,this article reviews the potential therapeutic targets and small molecule ligands of Fn in order to provide a reference for the development of anti-Fn and antiCRC small molecule drugs.